The following is a summary of the Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Supernus Pharmaceuticals reported Q2 2024 total revenue of $168.3 million, up from $135.5 million in Q2 2023.

• Qelbree showed significant growth with a 92% increase in net sales totaling $59 million for Q2 2024.

• GOCOVRI net sales increased by 10% year-over-year to $32 million in Q2 2024.

• Net earnings for Q2 2024 were $19.9 million, or $0.36 per diluted share, compared to a net loss of $831,000 in Q2 2023.

Business Progress:

• Supernus expanded its product pipeline with SPN-817 for treatment-resistant seizures and SPN-820 for depression.

• Anticipate commencement of Phase 2b study with SPN-817 by end of 2024 and results from Phase 2b study of SPN-820 in H1 2025.

• Activities to strengthen market positioning include strategic corporate development initiatives targeting growth opportunities.

Opportunities:

• The company expects continued growth driven by key products like Qelbree and GOCOVRI.

Risks:

• Anticipated entry of a generic competitor for Oxtellar XR later in 2024 poses a risk to sales projections.

More details: Supernus Pharmaceuticals IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.